Your browser doesn't support javascript.
Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants.
Ozawa, Tatsuhiko; Tani, Hideki; Anraku, Yuki; Kita, Shunsuke; Igarashi, Emiko; Saga, Yumiko; Inasaki, Noriko; Kawasuji, Hitoshi; Yamada, Hiroshi; Sasaki, So-Ichiro; Somekawa, Mayu; Sasaki, Jiei; Hayakawa, Yoshihiro; Yamamoto, Yoshihiro; Morinaga, Yoshitomo; Kurosawa, Nobuyuki; Isobe, Masaharu; Fukuhara, Hideo; Maenaka, Katsumi; Hashiguchi, Takao; Kishi, Hiroyuki; Kitajima, Isao; Saito, Shigeru; Niimi, Hideki.
  • Ozawa T; Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Tani H; Department of Virology, Toyama Institute of Health, Toyama, Japan.
  • Anraku Y; Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Kita S; Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Igarashi E; Department of Virology, Toyama Institute of Health, Toyama, Japan.
  • Saga Y; Department of Virology, Toyama Institute of Health, Toyama, Japan.
  • Inasaki N; Department of Virology, Toyama Institute of Health, Toyama, Japan.
  • Kawasuji H; Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Yamada H; Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Sasaki SI; Section of Host Defences, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Japan.
  • Somekawa M; Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Sasaki J; Laboratory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Hayakawa Y; Section of Host Defences, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Japan.
  • Yamamoto Y; Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Morinaga Y; Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Kurosawa N; Department of Life Sciences and Bioengineering, Laboratory of Molecular and Cellular Biology, Faculty of Engineering, Academic Assembly, University of Toyama, Toyama, Japan.
  • Isobe M; Department of Life Sciences and Bioengineering, Laboratory of Molecular and Cellular Biology, Faculty of Engineering, Academic Assembly, University of Toyama, Toyama, Japan.
  • Fukuhara H; Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Maenaka K; Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Hashiguchi T; Laboratory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Kishi H; Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Kitajima I; Administrative office, University of Toyama, Toyama, Japan.
  • Saito S; Administrative office, University of Toyama, Toyama, Japan.
  • Niimi H; Department of Clinical Laboratory and Molecular Pathology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
MAbs ; 14(1): 2072455, 2022.
Article in English | MEDLINE | ID: covidwho-1839974
ABSTRACT
Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Variants Limits: Humans Language: English Journal: MAbs Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: 19420862.2022.2072455

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Variants Limits: Humans Language: English Journal: MAbs Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: 19420862.2022.2072455